 Emergent BioSolutions Inc NYSE: EBS has agreed to acquire Chimerix Incs NASDAQ: CMRX exclusive worldwide rights to Tembexa brincidofovir, the first FDA-approved antiviral for all age groups for smallpox. It exemplifies our thoughtful MA strategy as. 